|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311. 2017.
View Article : Google Scholar
|
|
3
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Duma N, Santana-Davila R and Molina JR:
Non-small cell lung cancer: Epidemiology, screening, diagnosis, and
treatment. Mayo Clin Proc. 94:1623–1640. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ma L, Qiu B, Zhang J, Li QW, Wang B, Zhang
XH, Qiang MY, Chen ZL, Guo SP and Liu H: Survival and prognostic
factors of non-small cell lung cancer patients with postoperative
locoregional recurrence treated with radical radiotherapy. Chin J
Cancer. 36:932017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ai X, Guo X, Wang J, Stancu AL, Joslin
PMN, Zhag D and Zhu S: Targeted therapies for advanced non-small
cell lung cancer. Oncotarget. 9:37589–37607. 2018. View Article : Google Scholar
|
|
7
|
Li Z, Song Y, Liu L, Hou N, An X, Zhan D,
Li Y, Zhou L, Li P, Yu L, et al: miR-199a impairs autophagy and
induces cardiac hypertrophy through mTOR activation. Cell Death
Differ. 24:1205–1213. 2017. View Article : Google Scholar :
|
|
8
|
Mao M, Wu Z and Chen J: MicroRNA-187-5p
suppresses cancer cell progression in non-small cell lung cancer
(NSCLC) through down-regulation of CYP1B1. Biochem Biophys Res
Commun. 478:649–655. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mohr AM and Mott JL: Overview of microRNA
biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xie B, Ding Q, Han H and Wu D: miRCancer:
A microRNA-cancer association database constructed by text mining
on literature. Bioinformatics. 29:638–644. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rao C, Miao X, Zhao G, Zhang C, Shen H,
Dong C and Yang M: MiR-219a-5p enhances cisplatin sensitivity of
human non-small cell lung cancer by targeting FGF9. Biomed
Pharmacother. 114:1086622019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu W, He L, Huang Y, Hou L, Zhang W, Zhang
L and Wu C: MicroRNA-510 plays oncogenic roles in non-small cell
lung cancer by directly targeting SRC kinase signaling inhibitor 1.
Oncol Res. 27:879–887. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang MY, Lin J and Kui YC: MicroRNA-345
suppresses cell invasion and migration in non-small cell lung
cancer by directly targeting YAP1. Eur Rev Med Pharmacol Sci.
23:2436–2443. 2019.PubMed/NCBI
|
|
15
|
Liu S, Tian Y, Zhu C, Yang X and Sun Q:
High miR-718 suppresses phosphatase and tensin homolog (PTEN)
expression and correlates to unfavorable prognosis in gastric
cancer. Med Sci Monit. 24:5840–5850. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Leng R, Zha L and Tang L: MiR-718
represses VEGF and inhibits ovarian cancer cell progression. FEBS
Lett. 588:2078–2086. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang X and Qi M: miR-718 is involved in
malignancy of papillary thyroid cancer through repression of PDPK1.
Pathol Res Pract. 214:1787–1793. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang ZD, Qu FY, Chen YY, Ran ZS, Liu HY
and Zhang HD: Involvement of microRNA-718, a new regulator of EGR3,
in regulation of malignant phenotype of HCC cells. J Zhejiang Univ
Sci B. 18:27–36. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
20
|
Cooper WA, Kohonen-Corish MR, McCaughan B,
Kennedy C, Sutherland RL and Lee CS: Expression and prognostic
signifi-cance of cyclin B1 and cyclin A in non-small cell lung
cancer. Histopathology. 55:28–36. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yoshida T, Tanaka S, Mogi A, Shitara Y and
Kuwano H: The clinical significance of Cyclin B1 and Wee1
expression in non-small-cell lung cancer. Ann Oncol. 15:252–256.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Arinaga M, Noguchi T, Takeno S, Chujo M,
Miura T, Kimura Y and Uchida Y: Clinical implication of cyclin B1
in non-small cell lung cancer. Oncol Rep. 10:1381–1386.
2003.PubMed/NCBI
|
|
23
|
Zhang LL, Feng ZL, Su MX, Jiang XM, Chen
X, Wang Y, Li A, Lin LG and Lu JJ: Downregulation of Cyclin B1
mediates nagi-lactone E-induced G2 phase cell cycle arrest in
non-small cell lung cancer cells. Eur J Pharmacol. 830:17–25. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kedinger V, Meulle A, Zounib O, Bonnet ME,
Gossart JB, Benoit E, Messmer M, Shankaranarayanan P, Behr JP,
Erbacher P, et al: Sticky siRNAs targeting survivin and cyclin B1
exert an antitumoral effect on melanoma subcutaneous xenografts and
lung metastases. BMC Cancer. 13:3382013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mateen S, Raina K, Jain AK, Agarwal C,
Chan D and Agarwal R: Epigenetic modifications and p21-cyclin B1
nexus in anticancer effect of histone deacetylase inhibitors in
combination with silibinin on non-small cell lung cancer cells.
Epigenetics. 7:1161–1172. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zuryn A, Gagat M, Grzanka AA, Gackowska L
and Grzanka A: Expression of cyclin B1 after induction of
senescence and cell death in non-small cell lung carcinoma A549
cells. Folia Histochem Cytobiol. 50:58–67. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhuang XF, Zhao LX, Guo SP, Wei S, Zhai JF
and Zhou QH: miR-34b inhibits the migration/invasion and promotes
apoptosis of non-small-cell lung cancer cells by YAF2. Eur Rev Med
Pharmacol Sci. 23:2038–2046. 2019.PubMed/NCBI
|
|
28
|
Gao J, Feng X, Wang F, Wang J, Wang H, Li
H, Zhang W, Hao L and Shi Z: microRNA-448 inhibits the progression
of non-small-cell lung cancer through regulating IRS2. J Cell
Biochem. 120:13453–13463. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li H, Jiang M, Cui M, Feng G, Dong J, Li
Y, Xiao H and Fan S: MiR-365 enhances the radiosensitivity of
non-small cell lung cancer cells through targeting CDC25A. Biochem
Biophys Res Commun. 512:392–398. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Weidle UH, Birzele F and Nopora A:
MicroRNAs as potential targets for therapeutic intervention with
metastasis of non-small cell lung cancer. Cancer Genomics
Proteomics. 16:99–119. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang H, Ma Z, Liu X, Zhang C, Hu Y, Ding
L, Qi P, Wang J, Lu S and Li Y: MiR-183-5p is required for
non-small cell lung cancer progression by repressing PTEN. Biomed
Pharmacother. 111:1103–1111. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ma Y, Li X, Chen S, Du B and Li Y:
MicroRNA-4458 suppresses migration and epithelial-mesenchymal
transition via targeting HMGA1 in non-small-cell lung cancer cells.
Cancer Manag Res. 11:637–649. 2019. View Article : Google Scholar : PubMed/NCBI
|
